Prescriber's Corner
Advances in Myelofibrosis Management: New Janus Kinase Inhibitors Beyond Ruxolitinib
Justin Arnall, PharmD, BCOP, Lindsey Lyle, MS, PA-C, Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP et al.
May 22, 2024
Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Gwen Hua,(1) PharmD, BCOP, Ryan Scanlan,(2) PharmD Candidate, Rachael Straining,(1) PharmD, BCOP, and Daniel S. Carlson,(3) DO
March 22, 2023
Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes
Sara M. Tinsley-Vance,(1) PhD, APRN, AOCN®, Mark Davis,(2) MPAS, PA-C, and Olalekan Ajayi,(3) PharmD, MBA
January 18, 2023
Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma
Gwen Hua,(1) PharmD, Daniel Carlson,(2) DO, and Jacqueline R. Starr,(1) PharmD, BCOP
September 21, 2022
The Current Landscape for METex14 Skipping Mutations in Non–Small Cell Lung Cancer
Alisha Desai,(1) PharmD, and Sandra Cuellar,(2) PharmD, BCOP, FHOPA, FASHP
July 20, 2022
Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
Jessica Davis,(1) PharmD, BCOP, CPP, and Megan Wayman,(2) PharmD
May 18, 2022
Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Emily Behren Ketchum, PharmD, Andrea Clarke, PharmD, BCOP, and Amber B. Clemmons, PharmD, BCOP
January 19, 2022
Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer
Patrick J. Fleming Jr., PharmD, BCOP, Sylvia Karpio, PharmD candidate, and Nicholas Lombardo, PharmD candidate
September 22, 2021
Pegfilgrastim Biosimilars: Where Are We Now?
Christopher Selby,(1) PharmD, BCOP, Breanne Peyton-Thomas,(2) PharmD, BCOP, and Parnian Eslami,(3) PharmD
July 12, 2021
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
Donald C. Moore,(1) PharmD, BCPS, BCOP, DPLA, and Daniel Thompson,(2) PharmD
May 19, 2021
Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
Katherine V. Katsivalis, PharmD, and Jamie Thomas, PharmD
March 17, 2021
Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
Kristina F. Byers, PharmD, BCOP
January 20, 2021
Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
Avani Yenamandra,(1) PharmD, and Dennis Marjoncu,(2) PharmD, BCOP
November 18, 2020
Alpelisib: A Novel Therapy for Patients With <em>PIK3CA</em>-Mutated Metastatic Breast Cancer
Tori Wilhoit, PharmD, Jeannie M. Patrick, PharmD, BCOP, and Megan B. May, PharmD, BCOP
September 23, 2020
Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients
Melanie Douglas, MS, PA-C
July 22, 2020
Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
Kirollos S. Hanna, PharmD, BCPS, BCOP
May 27, 2020
Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
Danielle B. Dunn, PharmD
May 27, 2020
Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia
Daniel L. Thompson,(1) PharmD Candidate, and Donald C. Moore,(2) PharmD, BCPS, BCOP, DPLA
March 13, 2020
Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
Dennis Marjoncu,(1) PharmD, BCOP, and Benjamin Andrick,(2) PharmD, BCOP
January 20, 2020
Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Amber C. King, PharmD, BCOP, and Jennifer S. Orozco, PharmD
November 20, 2019
Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
Sutton Watson,(1) PharmD, and Justin Bradley Marx,(2) PharmD, BCPS
November 20, 2019
A Review of PI3K Inhibitors in B-Cell Malignancies
Laura Cannon,(1) PharmD, MPH, Emmeline C. Academia,(2) PharmD, and Ashley E. Glode,(2) PharmD, BCOP
September 18, 2019
Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
Kori Daniels, PharmD, and Amber Clemmons, PharmD, BCOP
September 18, 2019
Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
Shelby L. Merchant, PharmD, Kathryn Culos, PharmD, BCOP, and Houston Wyatt, PharmD, CSP
July 22, 2019
Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
Urvi J. Patel, PharmD, MPH, and Sarah Caulfield, PharmD, BCOP
July 22, 2019
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation
Sarah E. Caulfield, PharmD, BCOP, Christine C. Davis, PharmD, BCOP, and Kristina F. Byers, PharmD, BCOP
March 24, 2019
Methylnaltrexone: Peripherally Acting μ-Opioid Receptor Antagonist
Tanya J. Uritsky, PharmD, BCPS, CPE
January 21, 2019
Gemtuzumab Ozogamicin: Back Again
Chris Selby,(1) PharmD, BCOP, Lisa R. Yacko,(2) PharmD, BCPS, and Ashley E. Glode,(3) PharmD, BCOP
January 21, 2019
Trametinib: A Targeted Therapy in Metastatic Melanoma
Brianna Hoffner, MSN, ANP-BC, AOCNP®, and Katherine Benchich, MSN, NP-C, AOCNP®
November 27, 2018
Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
Jennifer Miles, PharmD, and Yahsin White, PharmD
November 27, 2018
Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Sherry Williams, PharmD, BCOP, and Miryoung Kim, PharmD, BCOP
September 14, 2018
Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
Bradley J. Yelvington, PharmD
July 24, 2018
Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
Craig W. Freyer, PharmD, BCOP
July 24, 2018
Current Issue
Immediate Patient Access to Test Results and the Impact on Advanced Practitioners
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO
November 26, 2024
Obinutuzumab Infusion-Related Reactions Multicenter Retrospective Evaluation of Incidence, Severity, and Risk Factors
Erin Hickey Zacholski, PharmD, BCOP, Sarah Rugh, PharmD Candidate, Jenna Marshall, PharmD Candidate, Et al.
November 26, 2024
Pancreatic Cancer The Advanced Practitioners Role in Early Diagnosis and Management
Lindsay Knox, FNP-C
November 26, 2024